Novel cancer stem marker and its applicability for grading primary human gliomas

9Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates (R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

Cite

CITATION STYLE

APA

Dolgova, E. V., Mishinov, S. V., Proskurina, A. S., Potter, E. A., Efremov, Y. R., Bayborodin, S. I., … Bogachev, S. S. (2018). Novel cancer stem marker and its applicability for grading primary human gliomas. Technology in Cancer Research and Treatment, 17, 1–8. https://doi.org/10.1177/1533034617753812

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free